Skip to main content
Premium Trial:

Request an Annual Quote

Roche, Evotec Partner on Protein Biomarkers for Cancer Drugs

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) –Roche and Evotec today announced a three-year agreement directed at biomarker discovery for use with oncology drugs under development by Roche.

Under the terms of the deal, Evotec will use its PhosphoScout platform for the discovery of protein phosphorylation biomarkers that may be used to determine the efficacy of targeted cancer drugs in patients and for dosing decisions.

The firms will conduct multiple biomarker programs for therapeutic antibodies or small-molecule inhibitors, and Roche will conduct clinical trials and assess the development of companion diagnostics for patient stratification. Evotec will receive undisclosed upfront and milestone payments for each program.

Further details of the deal were not disclosed.

PhosphoScout is a mass spectrometry-based platform for identifying and quantifying cellular phosphorylation events. According to Evotec, it offers unbiased systems-wide profiling of signaling pathways.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.